ClinicalTrials.gg
RecruitingNCT07886827Updated Oct 21, 2026

Functional Electrical Stimulation Combined With Exercise for Rotator Cuff-Related Shoulder Pain in Older Adults

An interventional study of Functional electrical stimulation and Sham Functional Electrical Stimulation in Rotator Cuff Disease, Subacromial Pain Syndrome and Shoulder Pain, sponsored by Lisa Griffin. Recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Lisa Griffin · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Oct 2025, registered Oct 2026).
  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 21, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether adding functional electrical stimulation (FES) to a shoulder exercise program improves how the shoulder muscles work together in older adults with rotator cuff-related shoulder pain. FES uses small electrical currents delivered through pads on the skin to help muscles contract.

The main questions it aims to answer are:

  1. Does exercise combined with FES improve coordination between the rotator cuff and deltoid muscles more than exercise alone?
  2. Does exercise combined with FES increase the space between the top of the upper arm bone and the shoulder blade (acromiohumeral distance), which may reduce pinching of the shoulder tendons?

Researchers will compare a group that receives resistance exercise with FES to a group that receives the same resistance exercise without FES.

Participants will:

  1. Attend exercise sessions 3 times per week for 4 weeks (12 sessions)
  2. Complete 4 testing visits: before training, after 2 weeks, after 4 weeks, and 4 weeks after training ends
  3. At each testing visit, perform shoulder strength tasks while muscle activity is recorded with sensors on the skin and thin wire sensors placed in the muscle, have an ultrasound of the shoulder, and complete questionnaires about shoulder pain and function
Read the detailed description

Subacromial shoulder pain is common in older adults and is associated with rotator cuff disease. The rotator cuff muscles stabilize the humeral head against the upward pull of the deltoid during arm elevation. Previous work from our laboratory showed that intermuscular EMG-EMG coherence between rotator cuff muscles increases during fatigue in healthy individuals but not in individuals with subacromial pain, suggesting impaired common neural drive to these muscles. Functional electrical stimulation (FES) has been shown to increase corticospinal excitability and muscle activation, but its long-term effects on neuromuscular coordination of the shoulder have not been studied.

This randomized controlled trial evaluates whether a 4-week resistance training program combined with FES improves neuromuscular control of the supraspinatus, infraspinatus, and middle deltoid compared with the same training without FES. Neuromuscular control is assessed using surface and intramuscular (fine-wire) EMG during isometric shoulder abduction at 25%, 50%, and 75% of maximal voluntary contraction, during ramp contractions, and during a sustained fatiguing contraction. Acromiohumeral distance and supraspinatus tendon occupation ratio are measured with ultrasound at 0°, 45°, and 60° of shoulder abduction.

02

Conditions studied

  • Rotator Cuff Disease
  • Subacromial Pain Syndrome
  • Shoulder Pain
  • Subacromial Impingement Syndrome

Keywords

  • Neuromuscular Electrical Stimulation
  • Functional Electrical Stimulation
  • Resistance Training
  • Older Adults
  • Eletromyography
  • Intermuscular Coherence
  • Acromiohumeral Distance
  • Shoulder Ultrasound Imaging
  • Shoulder Pain and Disability Index
03

In context

Shoulder Pain

724 studies on the registry are indexed under Shoulder Pain; 152 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 577 interventional studies indexed under Shoulder Pain.

Browse Shoulder Pain studies →

Lead sponsor

Lisa Griffin is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having pain more than 2 weeks in the anterolateral shoulder region
  • A painful arc of movement (60°-120°)
  • Having shown positive impingement signs, including positive Neer, Hawkins, and Empty Can tests

Exclusion criteria

Exclusion Criteria:

  • Acute diagnosed rotator cuff tears
  • Osteoarthritis-induced shoulder pain
  • Currently receiving treatment or physical therapy for shoulder pain
  • Previous shoulder surgery
  • Taking medications that affect the central nervous system
  • Metabolic or cardiovascular disease
  • Metal Implants or pacemakers
  • Skin lesions on the shoulder
  • Aversion to needles
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    FES + Resistance Training

    Participants perform a standardized 3-phase progressive resistance training program 3 times per week for 4 weeks (12 sessions, 20-30 minutes each) while receiving functional electrical stimulation (NEUBIE stimulator) to the supraspinatus and infraspinatus muscles (40 Hz, 0.46 ms pulse width, maximum comfortable intensity).

    Device: Functional electrical stimulation · Behavioral: Progressive Resistance Training

  • Sham comparator
    Sham FES + Resistance Training

    Participants perform the same standardized 3-phase progressive resistance training program 3 times per week for 4 weeks (12 sessions, 20-30 minutes each). Stimulation electrodes are placed over the supraspinatus and infraspinatus muscles using the same setup procedure as the FES group, but the NEUBIE stimulator intensity is set to 0, so no electrical current is delivered.

    Device: Sham Functional Electrical Stimulation · Behavioral: Progressive Resistance Training

Interventions

  • DeviceFunctional electrical stimulation

    Pulsed direct current electrical stimulation delivered by the NEUBIE stimulator through surface electrodes placed over the supraspinatus and infraspinatus muscles during resistance exercises (40 Hz, 0.46 ms pulse width, maximum comfortable intensity).

    Also known as: NEUBIE, FES, Pulsed Direct Current Electrical Stimulation

  • DeviceSham Functional Electrical Stimulation

    Identical electrode placement over the supraspinatus and infraspinatus and identical NEUBIE stimulator setup as the active FES intervention, applied during the same resistance exercises, with stimulator intensity set to 0 so that no electrical current is delivered.

    Also known as: Sham FES

  • BehavioralProgressive Resistance Training

    A standardized 3-phase progressive resistance training program (Michener et al., 2024) using elastic resistance bands, performed 3 times per week for 4 weeks under supervision by research staff. Participants progress through phases based on performance and symptom tolerance.

06

What researchers measure

Primary outcomes

  1. Intermuscular EMG Coherence During Submaximal Isometric Contractions

    EMG-EMG coherence between muscle pairs (supraspinatus-infraspinatus, supraspinatus-middle deltoid, infraspinatus-middle deltoid) recorded with surface and fine-wire electromyography during 30-second sustained isometric shoulder scaption at 25%, 50%, and 75% of maximal voluntary contraction. Coherence is quantified in the delta (2-5 Hz), alpha (5-15 Hz), and beta (15-35 Hz) frequency bands. Coherence values range from 0 (no shared neural drive) to 1 (complete shared neural drive).

    Time frame: Baseline, 2 weeks (mid-intervention), 4 weeks (end of intervention), and 8 weeks (4 weeks after the end of intervention)

  2. Intermuscular EMG Coherence During a Fatiguing Contraction

    EMG-EMG coherence between muscle pairs (supraspinatus-infraspinatus, supraspinatus-middle deltoid, infraspinatus-middle deltoid) in the delta (2-5 Hz), alpha (5-15 Hz), and beta (15-35 Hz) frequency bands during a sustained isometric contraction at 25% of maximal voluntary contraction held until the endurance limit (force drop of 5% MVC). Values range from 0 (no shared neural drive) to 1 (complete shared neural drive).

    Time frame: Baseline, 2 weeks (mid-intervention), 4 weeks (end of intervention), and 8 weeks (4 weeks after the end of intervention)

Secondary outcomes

  1. Acromiohumeral Distance

    Shortest linear distance between the inferior edge of the acromion and the humeral head, measured with ultrasound at rest (0° abduction) and during active shoulder abduction at 50% MVC at 45° and 60°. Each value is the average of 3 measurements. Measured in centimeters.

    Time frame: Baseline, 2 weeks (mid-intervention), 4 weeks (end of intervention), and 8 weeks (4 weeks after the end of intervention)

  2. Supraspinatus Tendon Occupation Ratio

    Ratio of supraspinatus tendon thickness to acromiohumeral distance, calculated as (tendon thickness / AHD) × 100, measured with ultrasound at 0°, 45°, and 60° of shoulder abduction. Each value is the average of 3 measurements. Expressed as a percentage.

    Time frame: Baseline, 2 weeks (mid-intervention), 4 weeks (end of intervention), and 8 weeks (4 weeks after the end of intervention)

  3. Shoulder Pain and Disability Index (SPADI)

    Self-administered questionnaire assessing shoulder pain and difficulty with upper-extremity activities of daily living. Total score ranges from 0 to 100, with higher scores indicating greater pain and disability.

    Time frame: Baseline, 2 weeks (mid-intervention), 4 weeks (end of intervention), and 8 weeks (4 weeks after the end of intervention)

  4. Muscle Fatigue Rate

    Slope of the EMG median frequency over time for the supraspinatus, infraspinatus, and middle deltoid during the sustained fatiguing contraction, calculated from surface and fine-wire EMG. A steeper negative slope indicates faster fatigue.

    Time frame: Baseline, 2 weeks (mid-intervention), 4 weeks (end of intervention), and 8 weeks (4 weeks after the end of intervention)

  5. Muscle Onset Time During Ramp Contractions

    Onset time of the supraspinatus, infraspinatus, and middle deltoid relative to force onset during isometric shoulder abduction ramp contractions (0 to 100% MVC at 7.5% MVC/s). Onset is defined as EMG amplitude exceeding 3 standard deviations of resting baseline for at least 25 ms. Measured in milliseconds.

    Time frame: Baseline, 2 weeks (mid-intervention), 4 weeks (end of intervention), and 8 weeks (4 weeks after the end of intervention)

  6. Motor Unit Recruitment Threshold

    Force level at which individual motor units in the supraspinatus and middle deltoid are recruited during ramp contractions, identified from fine-wire EMG as the first of four consecutive spikes. Expressed as percentage of maximal voluntary contraction (% MVC).

    Time frame: Baseline, 2 weeks (mid-intervention), 4 weeks (end of intervention), and 8 weeks (4 weeks after the end of intervention)

  7. Motor Unit Initial Firing Rate

    Firing rate of individual supraspinatus and middle deltoid motor units at recruitment during ramp contractions, calculated as the average of the first three inter-spike intervals. Measured in hertz (Hz).

    Time frame: Baseline, 2 weeks (mid-intervention), 4 weeks (end of intervention), and 8 weeks (4 weeks after the end of intervention)

07

Study locations

1 of 1 sites recruiting
  • The University of Texas at Austin, Austin, Texas, 78712
    Austin, Texas 78703, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2028, 35 months after the start.

Of 327 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 35 months is above that.

Counting every sponsor, half of 336 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 21, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07886827
Lead sponsor
Lisa Griffin
Responsible party
Lisa Griffin (Associate Professor, University of Texas at Austin) — Sponsor-investigator
First posted
Oct 21, 2026
Start date
Oct 1, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Ziwei Luo, M.Sc.
Contact
ziweil@utexas.edu
5125905388

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion